甲状腺功能亢进性心脏病76例临床分析  

The clinical analysis of 76 cases hyperthyroidism heart disease

作　　者：祁朝阳[1] 

机构地区：[1]丹江口市第一医院内分泌科,湖北丹江口442700

出　　处：《临床和实验医学杂志》2012年第9期661-662,共2页Journal of Clinical and Experimental Medicine

摘　　要：目的分析甲状腺功能亢进性心脏病患者的临床特点。方法选择2001年2月至2008年2月间内分泌科诊治的甲状腺功能亢进性心脏病患者76例为观察组,另选择98例单纯甲状腺功能亢进患者为对照组,分析甲状腺功能亢进性心脏病危险因素。应用碘剂治疗,根据患者病情不同辅以β-受体阻滞剂(如普萘洛尔)、利尿剂及洋地黄类药物,治疗周期为6个月。结果观察组患者年龄大于对照组,病程长于对照组,其差异均有统计学意义(P<0.01)。观察组患者血FT4平均为(63.85±13.76)pmol/L,明显高于对照组,差异有统计学意义(P<0.05)。两组患者性别构成比、血FT3及TSH水平间无统计学差异(P>0.05)。经6个月规范治疗,76例甲状腺功能亢进性心脏病患者痊愈54例(71.1%),缓解15例(19.7%),无效7例(9.2%)。其中5例无效患者经二次治疗后获得缓解,2例治愈。结论甲状腺功能亢进性心脏病发病与患者年龄、病程及FT4水平有关,碘剂(I131)对甲状腺功能亢进性心脏病具有较好的疗效。Objective To analyze the clinical features of hyperthyroidism heart disease.Methods Seventy-six hyperthyroidism heart disease patients treated from February 2001 to February 2008 were chosen as the observation group,98 patients with simple hyperthyroidism were chosen as the control.The risk factors were analyzed,and iodine treatment were performed.Results The patients were older and had longer disease duration than the control group（P0.01）.The mean serum FT4 in hyperthyroidism heart disease patients was 63.85±13.76 pmol/L,significantly higher than the control（P0.05）.There were no statistically significant difference in sex ratio,serum FT3 and TSH levels between the two groups（P0.05）.After 6 months of standard treatment,54 hyperthyroidism heart disease patients（71.1%） were cured,15（19.7%） had remission,7（9.2%） were invalid.After secondary treatment,5 hyperthyroidism heart disease patients had remission,2 patients were cured.Conclusion Hyperthyroidism heart disease relates with age,disease duration and the level of FT4 of the patients.Iodine（I131） has good effect in the treatment of hyperthyroidism heart disease.

关 键 词：甲状腺功能亢进性心脏病 临床特点 碘剂 治疗 

分 类 号：R541.85[医药卫生—心血管疾病]